Literature DB >> 18087199

DNA hypermethylation status of multiple genes in papillary thyroid carcinomas.

Eiwa Ishida1, Mitsutoshi Nakamura, Keiji Shimada, Tomonori Higuchi, Keisuke Takatsu, Katsunari Yane, Noboru Konishi.   

Abstract

OBJECTIVE: The aim of this study was hypermethylation of multiple genes for papillary thyroid carcinomas (PTCs).
METHODS: We examined 39 lesions using methylation-specific PCR to assess hypermethylation in genes, including p16(INK4a), p14(ARF), RB1, p27(Kip1)and 0(6)-MGMT. Homozygous deletions of p16(INK4a) and p14(ARF) were investigated by differential PCR, all with reference to clinicopathological factors.
RESULTS: We found methylation of p16(INK4a) in 35.9% (14/39); p14(ARF) in 2.6% (1/39); RB1 in 23.1% (9/39); p27(Kip1) in 15.4% (6/39),and 0(6)-MGMT in 15.4% (6/39). Hypermethylation of at least one of these genes was apparent in 66.7% (26/39). Homozygous deletions of p14(ARF) and p16(INK4a) were detected in 7.7 (3/39) and 2.6% (1/39), respectively. In cases with p16(INK4a) alterations, tumors were significantly increased. A history of chronic thyroid disease and lymphocytic infiltration was significantly associated with p14(ARF) alterations, without regional lymph node metastases.
CONCLUSIONS: Our data suggest that alterations in p16(INK4a), mainly hypermethylation, may be linked to tumor growth but not tumor development, while alterations in p14(ARF) may contribute to the induction of chronic inflammation-related PTCs. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18087199     DOI: 10.1159/000110028

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  10 in total

1.  Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.

Authors:  Javad Mohammadi-asl; Bagher Larijani; Zhamak Khorgami; Seyed Mohammad Tavangar; Vahid Haghpanah; Majid Kheirollahi; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-06-10       Impact factor: 3.064

2.  Common genetic variants related to genomic integrity and risk of papillary thyroid cancer.

Authors:  Gila Neta; Alina V Brenner; Erich M Sturgis; Ruth M Pfeiffer; Amy A Hutchinson; Briseis Aschebrook-Kilfoy; Meredith Yeager; Li Xu; William Wheeler; Michael Abend; Elaine Ron; Margaret A Tucker; Stephen J Chanock; Alice J Sigurdson
Journal:  Carcinogenesis       Date:  2011-06-03       Impact factor: 4.944

3.  Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.

Authors:  Michael J Demeure; Meraj Aziz; Richard Rosenberg; Steven D Gurley; Kimberly J Bussey; John D Carpten
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

Review 4.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

5.  Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.

Authors:  Mariana Brait; Myriam Loyo; Eli Rosenbaum; Kimberly L Ostrow; Alina Markova; Silvana Papagerakis; Marianna Zahurak; Steven M Goodman; Martha Zeiger; David Sidransky; Christopher B Umbricht; Mohammad O Hoque
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

6.  Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.

Authors:  Constantinos Giaginis; Christina Michailidi; Vasileios Stolakis; Paraskevi Alexandrou; Gerasimos Tsourouflis; Jerzy Klijanienko; Ioanna Delladetsima; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2011-02-25

7.  The role of epigenetic alterations in papillary thyroid carcinogenesis.

Authors:  Ogechukwu P Eze; Lee F Starker; Tobias Carling
Journal:  J Thyroid Res       Date:  2011-06-14

8.  Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.

Authors:  Fatemeh Khatami; Bagher Larijani; Ramin Heshmat; Abbasali Keshtkar; Mahsa Mohammadamoli; Ladan Teimoori-Toolabi; Shirzad Nasiri; Seyed Mohammad Tavangar
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

9.  Investigation of DNA repair-related SNPs underlying susceptibility to papillary thyroid carcinoma reveals MGMT as a novel candidate gene in Belarusian children exposed to radiation.

Authors:  Christine Lonjou; Francesca Damiola; Monika Moissonnier; Geoffroy Durand; Irina Malakhova; Vladimir Masyakin; Florence Le Calvez-Kelm; Elisabeth Cardis; Graham Byrnes; Ausrele Kesminiene; Fabienne Lesueur
Journal:  BMC Cancer       Date:  2017-05-12       Impact factor: 4.430

10.  CpG island status as an epigenetic alteration for NIS promoter in thyroid neoplasms; a cross-sectional study with a systematic review.

Authors:  Maryam Zarkesh; Noman Arab; Raziyeh Abooshahab; Shabnam Heydarzadeh; Sara Sheikholeslami; Zahra Nozhat; Marziyeh Salehi Jahromi; Seyed Ahmad Fanaei; Mehdi Hedayati
Journal:  Cancer Cell Int       Date:  2022-10-11       Impact factor: 6.429

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.